Showing 3981-3990 of 5300 results for "".
- Practical Dermatology Preview: Drug Companies, Insurance Companies, Pharmacists, the Government, Doctors and…Oh, Patients!https://practicaldermatology.com/news/practical-dermatology-preview-drug-companies-insurance-companies-pharmacists-the-government-doctors-andoh-patients/2458774/Recently, a relationship between Valeant Pharmaceuticals and a specialty pharmacy, Philidor, was revealed, with significant consequences to Valeant and equally significant consequences for the pharmacy. The full story is still unfolding as of this time, but the interpretations of these type
- ASDS Goes Triple Platinum in MarCom Awardshttps://practicaldermatology.com/news/asds-goes-triple-platinum-in-marcom-awards/2458778/The American Society for Dermatologic Surgery and American Society for Dermatologic Surgery Association were recognized with 14 awards – including three Platinums – in the 2015 MarCom Awards competition. The MarCom Awards is an international competition administered and judged by the
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- Lumenis UltraPulse Technology is Being Used to Treat Kim Phuc “The Girl in the Picture”https://practicaldermatology.com/news/lumenis-ultrapulse-technology-is-being-used-to-treat-kim-phuc-the-girl-in-the-picture/2458821/Lumenis Ltd.’s UltraPulse laser is being used by Jill Waibel, MD to treat scars on Kim Phuc, a survivor of a Vietnam War bombing in 1972. The UltraPulse was chosen for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars. Kim Phuc, a
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- Benzac Skin Refining Mask and Benzac Acne Eliminating Cleanser from Galderma Now Available Nationwidehttps://practicaldermatology.com/news/benzac-skin-refining-mask-and-benzac-acne-eliminating-cleanser-from-galderma-now-available-nationwide/2458893/
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi